Lilly bags first cluster headache use for migraine prevention drug from FDA

The US Food and Drug Administration has approved Emgality (galcanezumab-gnlm) solution for injection for the treatment of episodic cluster headache in adults.

US pharma major Eli Lilly’s (NYSE: LLY) Emgality is given by patient self-injection. It was first approved by the FDA in September 2018 for the preventive treatment of migraine in adults.

“Emgality provides patients with the first FDA-approved drug that reduces the frequency of attacks of episodic cluster headache, an extremely painful and often debilitating condition,” said Dr Eric Bastings, deputy director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “The FDA is committed to continuing to work with drug developers to bring treatments for unmet medical needs to patients.”